Business Overview

Vivakor, Inc. (“Vivakor,” the “Company,” or “we”) is a transdisciplinary research company that develops products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds.  We also provide contract research services for third parties.  We have developed numerous products and have filed many patents or provisional patents with the United States Patent and Trademark Office (USPTO).  We intend to commercialize such products, after completion of any required regulatory approvals, through one of three methods:  a sale of the technology, licensing of the product to a manufacturer or distributor or, in some cases, by manufacturing, marketing and directly selling the products ourselves.

Our business model is to be a research hub focused on areas that have both an identified scientific need and a substantial market opportunity.  Our company mission is to advance new ideas to improve the quality of life for individual patients, researchers, clinician or consumer.  We believe that the development of substantive technologies and cures for complex human conditions, illnesses and diseases require a sophisticated approach with contribution from many areas of scientific expertise typically requiring a lengthier trajectory to market.  Our hub approach is intended to provide the necessary environment of transdisciplinary collaboration and cross-pollination to advance this type of research.  Our research is anchored by our relationship with collaborative partners and product-specific commercialization strategies.  From the commencement of product conception through development, we target specific commercialization strategies and expect to have collaborative partners or licensing arrangements in place for each of our products before completion.  We expect this model to offer several advantages to our shareholders, including a more efficient research and development process and a quicker time to market after completion of development.

Our pathway for development of products follows one of two routes to commercialization.  First is a short-term path in which products for which an expedited regulatory oversight is available are rapidly pushed to the prototype and alpha testing phase.  These projects represent rapidly commercializable technologies and products that we expect will have the potential to generate revenue quickly.  Second is a long-term path in which more involved and complex projects are developed.  These products typically require substantial regulatory oversight or approval.  We anticipate that cash flow generated by the short-term projects will help to fund the long-term projects.  These longer incubating projects characteristically represent breakthrough technologies with more risk but higher revenue potential.